Compare Amgen, Inc. (AMGN) vs PubMatic Inc (PUBM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs PubMatic Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while PubMatic Inc trades at $13.55 (market cap $628.84M). The key difference: Amgen, Inc. is far larger — about 311.9× PubMatic Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals.
| AMGN | PUBM | |
|---|---|---|
Market Cap | $196.12B | $628.84M |
Sector | Health | Technology |
52-Week High | $388.16 | $13.83 |
52-Week Low | $271.18 | $6.28 |
Enterprise Value | $241.41B | $526.35M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
PubMatic (PUBM) trades at $13.55, showing minimal daily movement (-0.07%) with a bullish technical outlook supported by moving averages. The company reported mixed Q1 2026 results, beating EPS expectations but posting a net loss, while maintaining strong operational cash flow of $81M in 2025. Recent partnerships with Level Agency and Gracenote highlight growth in AI-powered advertising and CTV markets.
Investment outlook balances analyst optimism (50% buy ratings, $17 consensus target) against fundamental challenges including negative profit margins and elevated P/E ratio. Key risks include competitive pressure in ad tech and execution on AI initiatives, while institutional sentiment remains divided between growth potential and current profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
